Mon, March 25, 2013
Sun, March 24, 2013
Fri, March 22, 2013
Thu, March 21, 2013
Wed, March 20, 2013
[ Wed, Mar 20th 2013 ] - Market Wire
00am ET
Tue, March 19, 2013
Mon, March 18, 2013
Sun, March 17, 2013
Fri, March 15, 2013
Thu, March 14, 2013
Wed, March 13, 2013
Tue, March 12, 2013
Mon, March 11, 2013
Sun, March 10, 2013
Sat, March 9, 2013
Fri, March 8, 2013
Thu, March 7, 2013
Wed, March 6, 2013
[ Wed, Mar 06th 2013 ] - Market Wire
Alchemia Granted Key US Patent
Tue, March 5, 2013
Mon, March 4, 2013
Sun, March 3, 2013
Sat, March 2, 2013
Fri, March 1, 2013
Thu, February 28, 2013
Wed, February 27, 2013

Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results


//health-fitness.news-articles.net/content/2013/ .. rter-and-fiscal-year-2012-financial-results.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Alimera Sciences To Release Fourth Quarter And Fiscal Year 2012 Financial Results -- ATLANTA, March 11, 2013 /PRNewswire/ --

ATLANTA, March 11, 2013 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: [ ALIM ]) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2012 financial results after the market close on Thursday, March 21, 2013. An investor conference call will follow on the same day at 4:30 p.m. ET.

The conference call will be hosted by Dan Myers , President and Chief Executive Officer, and Rick Eiswirth , Chief Operating Officer and Chief Financial Officer.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at [ http://www.alimerasciences.com ].

A replay of the conference call will be available beginning March 21, 2013 at 7:30 p.m. ET and ending on March 28, 2013 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 19269391. A replay of the webcast will be available on the corporate website for one week, through March 28, 2013.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its primary product, ILUVIEN, is an intravitreal implant containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease.

Investor Contact:  
ICR, LLC  
John Mills  
310-954-1105  
[ John.Mills@icrinc.com ]   

SOURCE Alimera Sciences, Inc.



RELATED LINKS
[ http://www.alimerasciences.com ]

Publication Contributing Sources